Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
PsA , a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF inhibitors have revolutionized treatment of the disease and expanded the PsA therapy market to a multibillion-dollar entity. In recent years, several novel therapies with alternative MOA s, such as the IL -12/23 inhibitor ustekinumab, the oral PDE -4 inhibitor apremilast, and the IL -17A inhibitor secukinumab, have entered this market and notably improved the outcome of patients who have an inadequate response to TNF inhibitors.
Three biologics and three oral agents are in late-stage development for PsA and are expected to launch during the 2016-2026 study period. Thought-leading physicians describe a dynamic patient-management environment with a growing need for additional novel therapies. In this content, we analyze physician perception and anticipated positioning of these agents and the implications for the market-leading TNF inhibitor class.